Impax Asset Management Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-2,587
| Closed | -$495K | – | 309 |
|
|
2023
Q4 | $495K | Sell |
2,587
-316
| -11% | -$60.5K | ﹤0.01% | 340 |
|
|
2023
Q3 | $514K | Sell |
2,903
-165
| -5% | -$29.2K | ﹤0.01% | 330 |
|
|
2023
Q2 | $583K | Buy |
3,068
+48
| +2% | +$9.12K | ﹤0.01% | 327 |
|
|
2023
Q1 | $605K | Buy |
3,020
+312
| +12% | +$62.5K | ﹤0.01% | 308 |
|
|
2022
Q4 | $644K | Sell |
2,708
-954
| -26% | -$227K | ﹤0.01% | 298 |
|
|
2022
Q3 | $733K | Buy |
3,662
+350
| +11% | +$70.1K | ﹤0.01% | 290 |
|
|
2022
Q2 | $483K | Sell |
3,312
-786
| -19% | -$115K | ﹤0.01% | 325 |
|
|
2022
Q1 | $669K | Buy |
4,098
+307
| +8% | +$50.1K | ﹤0.01% | 322 |
|
|
2021
Q4 | $642K | Sell |
3,791
-12,521
| -77% | -$2.12M | ﹤0.01% | 332 |
|
|
2021
Q3 | $3.08M | Buy |
16,312
+66
| +0.4% | +$12.5K | 0.01% | 220 |
|
|
2021
Q2 | $2.75M | Buy |
16,246
+1
| +0% | +$170 | 0.01% | 226 |
|
|
2021
Q1 | $2.29M | Buy |
16,245
+110
| +0.7% | +$15.5K | 0.01% | 234 |
|
|
2020
Q4 | $2.1M | Sell |
16,135
-35,031
| -68% | -$4.55M | 0.01% | 201 |
|
|
2020
Q3 | $7.45M | Buy |
51,166
+21,074
| +70% | +$3.07M | 0.07% | 129 |
|
|
2020
Q2 | $4.46M | Buy |
30,092
+8,754
| +41% | +$1.3M | 0.05% | 160 |
|
|
2020
Q1 | $2.32M | Buy |
21,338
+18,879
| +768% | +$2.06M | 0.03% | 187 |
|
|
2019
Q4 | $283K | Buy |
+2,459
| New | +$283K | ﹤0.01% | 263 |
|